Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | AURKA | O14965 | 1/20 | 0.74 |
| ▸ | FGR | P09769 | 1/20 | 0.74 |
| ▸ | SRC | P12931 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.74 |
| ▸ | CD69 | Q07108 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21776837 | 1.00 | BTK (0.96) | BTKKCNH2CYP2C9AURKAFGR | |
| SCHEMBL31683874 | 1.00 | BTK (0.96) | BTKKCNH2CYP2C9AURKAFGR | |
| SCHEMBL21791236 | 1.00 | BTK (0.96) | BTKKCNH2CYP2C9AURKAFGR | |
| SCHEMBL30104454 | 1.00 | BTK (0.96) | BTKKCNH2CYP2C9AURKAFGR | |
| SCHEMBL24703852 | 0.98 | BTK (1.00) | BTKKCNH2CYP2C9AURKAFGR | |
| SCHEMBL21791320 | 0.91 | BTK (0.81) | BTKKCNH2CYP2C9AURKAFGR | |
| SCHEMBL30104383 | 0.91 | BTK (0.81) | BTKKCNH2CYP2C9AURKAFGR | |
| SCHEMBL24704301 | 0.90 | BTK (1.00) | BTKKCNH2CYP2C9AURKAFGR | |
| SCHEMBL24704060 | 0.90 | BTK (0.82) | BTKKCNH2CYP2C9AURKAFGR | |
| SCHEMBL21791298 | 0.89 | BTK (0.83) | BTKKCNH2CYP2C9AURKAFGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415803-B2 | Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) | MERCK PATENT GMBH (DE) | 2025-09-16 | — | — | US | disclosed |
| US-20220389004-A1 | FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | EMD Serono Research and Development Institute, Inc. | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415803-B2 | Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) | BTK, SYK, ABL1 | BTK 1/4885KCNH2 2077/4885CYP2C9 2442/4885 |
| US-20220389004-A1 | FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, SYK, ABL1 | BTK 1/4885KCNH2 2077/4885CYP2C9 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.